Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Denosumab; Diphosphonates

Criteria

Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma

• At least one bone metastasis